Vonoprazan

Vonoprazan fumarate is a first-in-class potassium-competitive acid blocker. It was approved in the Japanese market in February 2015. Vonoprazan fumarate is a first-in-class potassium-competitive acid blocker. It was approved in the Japanese market in February 2015. Vonoprazan can be used for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori.